Immix Biopharma · pitchdeck
Immix Biopharma | Investor Presentation Deck | 58 slides
58 pages · 4 arc beats · 2 loops
Immix Biopharma | Investor Presentation Deck | 58 slides
Immix Biopharma · 2023-09 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234363840424446485052545658
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 58 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 3 slides 100% 3/3 slides 100% 3/3 slides · 10 hits — 0/3 slides
66.7% 2/3 slides 33.3% 1/3 slides 100% 3/3 slides — 0/3 slides
Interest 24 slides 100% 24/24 slides 100% 24/24 slides · 116 hits — 0/24 slides
50% 12/24 slides 58.3% 14/24 slides 100% 24/24 slides 16.7% 4/24 slides Desire 18 slides 100% 18/18 slides 100% 18/18 slides · 84 hits — 0/18 slides
55.6% 10/18 slides · 12 hits 38.9% 7/18 slides 100% 18/18 slides — 0/18 slides
Action 13 slides 100% 13/13 slides 100% 13/13 slides · 63 hits — 0/13 slides
46.2% 6/13 slides · 7 hits 15.4% 2/13 slides 100% 13/13 slides — 0/13 slides
Slide inventory
58 every slide · same image gating as the playbook
03
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Attention
04
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.frame_problem
Open slide detailBeat · Interest
06
The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.compare_peers
Open slide detailBeat · Interest
07
Uses a visual icon-grid to represent market expansion from 5% of hospitals to a much broader network.size_opportunity
Open slide detailBeat · Interest
08
The slide uses a molecular biology diagram to illustrate the structural difference in the binding domain of the NXC-201 therapy compared to competitors.present_solution
Open slide detailBeat · Interest
09
Includes comparative bar charts and flow cytometry data.present_solution
10
The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.compare_peers
11
The chart demonstrates the efficacy of NXC-201 (formerly HBI0101) in clearing diseased cells.show_traction
Open slide detailBeat · Interest
12
The slide uses a process flow diagram to connect cellular pathology to clinical symptoms in the heart, liver, and kidneys.frame_problem
Open slide detailBeat · Interest
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.compare_peers
Open slide detailBeat · Interest
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.compare_peers
Open slide detailBeat · Interest
16
Includes FDA approval precedents in the footer to establish credibility.plan_implementation
Open slide detailBeat · Interest
17
Includes detailed clinical trial citations in the footer.show_traction
Open slide detailBeat · Interest
18
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
Open slide detailBeat · Interest
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.present_solution
Open slide detailBeat · Interest
20
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and highlighting specific regulatory and clinical trialshow_traction
Open slide detailBeat · Interest
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.argue_timing
22
The slide uses a wave-like visual to represent market segments and their associated valuations.size_opportunity
24
The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).compare_peers
Open slide detailBeat · Interest
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).show_traction
Open slide detailBeat · Interest
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.compare_peers
Open slide detailBeat · Interest
27
The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.show_traction
Open slide detailBeat · Interest
28
The chart illustrates deepening responses over time in a clinical trial setting.show_traction
Open slide detailBeat · Desire
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).analyze_data
Open slide detailBeat · Desire
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).compare_peers
Open slide detailBeat · Desire
32
The diagram illustrates a classic dose-escalation study design.plan_implementation
Open slide detailBeat · Desire
33
The slide uses a mix of expert quotes and a comparative table of clinical trials to validate the outpatient therapy thesis.illustrate_case
Open slide detailBeat · Desire
34
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.transition
Open slide detailBeat · Desire
35
Includes scientific diagrams of molecular pathways and efficacy charts.present_solution
Open slide detailBeat · Desire
36
Slide contains three distinct data visualizations comparing IMX-110 against standard of care or historical benchmarks.show_traction
Open slide detailBeat · Desire
37
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in turning cold tumors hot.show_traction
Open slide detailBeat · Desire
38
Includes survival curves, median survival comparison, and bioluminescence imaging of tumor activity.show_traction
Open slide detailBeat · Desire
40
Includes waterfall chart for best percentage change and line charts for longitudinal tumor size tracking against PD/PR thresholds.show_traction
Open slide detailBeat · Desire
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines ocompare_peers
Open slide detailBeat · Desire
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.show_traction
Open slide detailBeat · Desire
43
Includes logos for BeiGene and Novartis at the bottom.plan_implementation
Open slide detailBeat · Desire
45
The slide uses a process-flow style layout to connect platform capabilities to specific therapeutic assets.present_solution
Open slide detailBeat · Desire
46
The slide uses a process-like structure to map the platform pillars to specific product outputs.present_solution
Open slide detailBeat · Action
47
Includes technical diagrams of the drug molecule, comparative histology, and survival curves.present_solution
Open slide detailBeat · Action
48
Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.show_traction
Open slide detailBeat · Action
49
The slide uses a combination of mechanism-of-action diagrams and clinical/preclinical data charts to validate the therapeutic approach.present_solution
Open slide detailBeat · Action
51
The slide is divided into two sections: ImmixBio Clinical Advisory Board and Select Nexcella Scientific Advisory Board Members.other
Open slide detailBeat · Action
53
The slide is organized into two rows, one for each board, featuring headshots, names, titles, and associated company logos.other
Open slide detailBeat · Action
54
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Action
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.compare_peers
Open slide detailBeat · Action
57
The slide uses a bar chart to compare two groups of oncology drugs, highlighting a significant revenue disparity.size_opportunity
Open slide detailBeat · Action
58
The slide uses a bar chart comparison to benchmark existing market leaders against placebo outcomes.compare_peers
Open slide detailBeat · Action